Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.59−0.67 (-6.53%)
Close on Nov 12, 2026Market cap $159.01MP/E –Yield –
Sutro Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sutro Biopharma's operating income for the twelve months ending Sep 30, 2026 was -$119.55M. For fiscal 2025 it was -$158.37M. The highest annual figure on record is $1.36M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$158.37M | – |
| FY2024 | Dec 31, 2024 | -$238.45M | – |
| FY2023 | Dec 31, 2023 | -$89.28M | – |
| FY2022 | Dec 31, 2022 | -$128.94M | – |
| FY2021 | Dec 31, 2021 | -$98.52M | – |
| FY2020 | Dec 31, 2020 | -$71.06M | – |
| FY2019 | Dec 31, 2019 | -$55.47M | – |
| FY2018 | Dec 31, 2018 | -$37.22M | – |
| FY2017 | Dec 31, 2017 | -$19.27M | -1512.9% |
| FY2016 | Dec 31, 2016 | $1.36M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$21.96M | – |
| Q2 FY2026 | Jun 30, 2026 | -$29.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.05M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.46M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$68.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$65.26M | -251.2% |
| Q3 FY2024 | Sep 30, 2024 | -$67.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$48.69M | – |
| Q1 FY2024 | Mar 31, 2024 | -$56.59M | – |
| Q4 FY2023 | Dec 31, 2023 | $43.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$44.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$46.18M | – |
| Q1 FY2023 | Mar 31, 2023 | -$42.24M | – |
| Q4 FY2022 | Dec 31, 2022 | -$49.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.38M | – |
| Q1 FY2022 | Mar 31, 2022 | -$39.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$34.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.81M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$24.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.78M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.74M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.69M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.27M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.28M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.70M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.17M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.07M | – |
See a number that looks wrong?